In Shin, MD
Ophthalmology · Montgomery, ALNPI 1245215656
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 359 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Kala Pharmaceuticals, Inc. at 27.1% of the total. Among ophthalmology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $33.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$3K
- AbbVie$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Alcon$1K
- Glaukos Corporation$745
- Bausch & Lomb, A Division Of Bausch Health US, LLC$691
- plus $3K from 21 others
What the payments were for
- Food & beverage$11,959100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kala Pharmaceuticals, Inc. | 38 | $3,244 |
| AbbVie(2 entities) | 100 | $2,458 |
| Johnson & Johnson Surgical Vision, Inc. | 36 | $1,119 |
| Alcon | 40 | $1,078 |
| Glaukos Corporation | 19 | $745 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 19 | $691 |
| Sight Sciences, Inc. | 9 | $357 |
| Tarsus Pharmaceuticals, Inc. | 16 | $296 |
| Ocular Therapeutix, Inc. | 11 | $268 |
| Bausch & Lomb Americas Inc. | 15 | $235 |
| NEW World Medical,inc. | 4 | $227 |
| Eyevance Pharmaceuticals LLC | 13 | $223 |
| Sun Pharmaceutical Industries Inc. | 7 | $152 |
| Dompe US, Inc. | 5 | $151 |
| Ivantis, Inc | 4 | $137 |
| Beaver-visitec International, Inc. | 1 | $108 |
| Rxsight Inc | 3 | $87 |
| Novartis | 4 | $65 |
| Biotissue Holdings Inc. | 3 | $60 |
| Oyster Point Pharma, Inc. | 2 | $60 |
| Thea Pharma Inc. | 2 | $40 |
| Shire North American Group Inc | 2 | $40 |
| Iridex Corporation | 2 | $38 |
| Nova Eye, Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Omeros Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVELTYS$1,985
- XEN GLAUCOMA TREATMENT SYSTEM$373
- Kahook Dual Blade$161
- Clearpath$161
- Ahmed Glaucoma Valve$161
- Streamline$161
- Via360$161
- iDoseTR$155
- VYZULTA$125
- Tecnis Simplicity$120
- DURYSTA$117
- AMO PHACO NEEDLE$117
- Hydrus Microstent$113
- Voyager DSLT$113
- Unity$109
- LUMIGAN$108
- COMBIGAN$108
- DEXTENZA$106
How this compares
$11,959 in reported general payments places this provider in the 95th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 11 | $454,276 |
| LumiganBimatoprost | 219 | $80,025 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 224 | $57,562 |
| Prednisolone Acetate | 1,249 | $44,687 |
| RocklatanNetarsudil Mesylat/Latanoprost | 81 | $33,124 |
| XdemvyLotilaner | 16 | $29,852 |
| Brimonidine Tartrate | 773 | $28,255 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 184 | $26,648 |
| RhopressaNetarsudil Mesylate | 55 | $25,050 |
| CombiganBrimonidine Tartrate/Timolol | 88 | $22,953 |
| Latanoprost | 1,307 | $20,948 |
| VyzultaLatanoprostene Bunod | 50 | $19,487 |
| RestasisCyclosporine | 21 | $19,456 |
| Cyclosporine | 21 | $16,628 |
| Alphagan PBrimonidine Tartrate | 38 | $11,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $151 | $454,27611 claims |
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $2,458 | $133,434366 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $17 | $58,174136 claims |
| AlconSimbrinza | $1,078 | $57,562224 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $296 | $29,85216 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $235 | $19,48750 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $691 | $9,36127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 197 ophthalmology providers in Alabama.
Other ophthalmology in Montgomery
- Stephen OwensMontgomery$10K
- Katherine DonnithorneMontgomery$7K
- John SwanMontgomery$6K
- James IzerMontgomery$6K
- Elizabeth MurphyMontgomery$4K
- Bret FisherHomewood$545K
- Caroline WatsonHuntsville$292K
- Ronald GrossFairhope$143K
- Kristin BainsBirmingham$40K
- Sebastian HeersinkDothan$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.